Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.
NASDAQ · AVTX
Avalo Therapeutics, Inc.
Healthcare · Biotechnology
$19.71
Down-$0.24 (-1.20%)
Updated Aug 19, 2026, 3:56 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 220.35M
- P/E ratio
- -2.73
- Dividend yield
- 0.00%
- 52-week range
- $12.51 – $24.27
- Volume
- 1.07M
- Avg. volume
- 410.27K
Price performance
AVTX price history
1M range · 21 trading sessions · Daily adjusted prices
AVTX closed at $19.71 after 21 trading sessions, up 4.73% for the selected period.
- Last close
- $19.71
- Period change
- +4.73%
- Period low
- $17.76
- Period high
- $19.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $19.91 | $20.46 | $19.62 | $19.71 | 1.07M |
| Aug 17, 2026 | $19.48 | $20.07 | $19.325 | $19.95 | 646.97K |
| Aug 14, 2026 | $19.13 | $19.63 | $18.34 | $19.59 | 388.07K |
| Aug 13, 2026 | $19.65 | $19.67 | $19.19 | $19.45 | 391.15K |
| Aug 12, 2026 | $19.52 | $19.77 | $19.27 | $19.55 | 317.25K |
| Aug 11, 2026 | $19.67 | $20.005 | $18.86 | $19.47 | 714.97K |
| Aug 10, 2026 | $18.25 | $20.00 | $18.00 | $19.77 | 977.86K |
| Aug 7, 2026 | $18.87 | $19.05 | $17.90 | $18.32 | 730.26K |
| Aug 6, 2026 | $17.87 | $19.84 | $17.87 | $18.70 | 596.21K |
| Aug 5, 2026 | $18.65 | $19.38 | $18.33 | $18.84 | 734.51K |
| Aug 4, 2026 | $18.37 | $18.69 | $17.64 | $18.53 | 1.16M |
| Aug 3, 2026 | $18.26 | $18.695 | $17.75 | $18.05 | 572.28K |
| Jul 31, 2026 | $19.50 | $19.73 | $18.24 | $18.25 | 923.88K |
| Jul 30, 2026 | $19.02 | $19.88 | $18.98 | $19.39 | 935.22K |
| Jul 29, 2026 | $19.68 | $19.795 | $18.71 | $19.01 | 789.79K |
| Jul 28, 2026 | $19.38 | $19.97 | $18.625 | $19.52 | 815.72K |
| Jul 27, 2026 | $18.495 | $20.01 | $18.315 | $19.50 | 1.17M |
| Jul 24, 2026 | $18.01 | $18.53 | $17.55 | $18.44 | 800.24K |
| Jul 23, 2026 | $17.84 | $18.28 | $17.75 | $17.76 | 527.83K |
| Jul 22, 2026 | $18.54 | $18.96 | $18.01 | $18.15 | 664.69K |
| Jul 21, 2026 | $18.11 | $19.01 | $18.09 | $18.82 | 1.11M |
Latest AVTX news
The latest Smart Investors Daily articles mentioning AVTX.
Stock researchCompany · Overview
AVTX research
Overview
Company profile and research snapshot.
Company profile
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $25.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 6, 2026 | Leerink Partners | Outperform | — |
| Jun 16, 2026 | BTIG | Buy | — |
| Jun 12, 2026 | B of A Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.
Benzinga · Aug 6, 2026
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share
Benzinga · Jul 28, 2026
Avalo Therapeutics Files Prospectus For Offering Up To 128,189 Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1534120/000110465926087573/tm2620167-5_424b3.htm
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
